文献速递糖尿病肥胖与代谢综合征

23个高收入司法管辖区2型糖尿病的终生风险、预期寿命与寿命损失年:一项跨国人群研究

Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-09-29

终生风险从苏格兰女性的16.3%到新加坡男性的59.6%不等;20岁2型糖尿病男性预期寿命最高为日本2017—18年的59.2年,最低为立陶宛2013—14年的43.7年。尽管许多地区终生风险下降且患者预期寿命改善,2型糖尿病负担仍然巨大。

要点

  • 23个高收入司法管辖区终生风险为16.3%(苏格兰女性)至59.6%(新加坡男性)。
  • 20岁2型糖尿病男性预期寿命最高为日本2017—18年的59.2年,最低为立陶宛2013—14年的43.7年。
  • 20岁男性寿命损失年从拉脱维亚2015—16年的2.5年至以色列Clalit健康服务2015—16年的12.9年。

核心结论

  • 尽管许多高收入司法管辖区终生风险下降且2型糖尿病患者预期寿命改善,2型糖尿病负担仍然巨大。
  • 公共卫生策略可能受益于量身定制的方法以持续改善糖尿病患者健康结局。

研究设计与样本

  • 跨国人群研究,数据来自23个司法管辖区(国家或地区)的24个数据库。
  • 采用按性别分层、年龄和日历年调整的泊松模型建模2型糖尿病发病率和死亡率。
  • 终生风险计算为20岁至100岁之间发生2型糖尿病的队列比例,95%CI采用参数自举法估计。

主要发现

  • 全部研究队列总人年1 577 234 194,2型糖尿病新发病例5 119 585例,2型糖尿病患者死亡4 007 064例,非2型糖尿病患者死亡11 854 043例。
  • 终生风险从苏格兰女性16.3%(95%CI 15.6—17.0)到新加坡男性59.6%(95%CI 58.5—60.8);在研究的15个有两个时间点的司法管辖区中,11个终生风险随时间下降。
  • 20岁2型糖尿病男性预期寿命最高为日本2017—18年59.2年(95%CI 59.2—59.3),女性64.1年(95%CI 64.0—64.2);最低为立陶宛2013—14年男性43.7年(95%CI 42.7—44.6)和拉脱维亚2010—11年女性54.2年(95%CI 53.4—54.9)。
  • 除西班牙和苏格兰外,所有司法管辖区男女2型糖尿病患者预期寿命随时间增加;拉脱维亚2010—11至2015—16和美国2009—10至2014—15的2型糖尿病与非2型糖尿病预期寿命差距大幅缩小。
  • 20岁男性寿命损失年从拉脱维亚2015—16年2.5年至以色列Clalit健康服务2015—16年12.9年;女性从芬兰2011—12年3.1年至以色列Clalit健康服务2010—11和2015—16年11.2年;美国2009—10至2014—15年20岁男性寿命损失年降幅最大,减少2.7年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes is a major public health issue. Because lifetime risk, life expectancy, and years of life lost are meaningful metrics for clinical decision making, we aimed to estimate these measures for type 2 diabetes in the high-income setting. METHODS: For this multinational, population-based study, we sourced data from 24 databases for 23 jurisdictions (either whole countries or regions of a country): Australia; Austria; Canada; Denmark; Finland; France; Germany; Hong Kong; Hungary; Israel; Italy; Japan; Latvia; Lithuania; the Netherlands; Norway; Scotland; Singapore; South Korea; Spain; Taiwan; the UK; and the USA. Our main outcomes were lifetime risk of type 2 diabetes, life expectancy in people with and without type 2 diabetes, and years of life lost to type 2 diabetes. We modelled the incidence and mortality of type 2 diabetes in people with and without type 2 diabetes in sex-stratified, age-adjusted, and calendar year-adjusted Poisson models for each jurisdiction. Using incidence and mortality, we constructed life tables for people of both sexes aged 20-100 years for each jurisdiction and at two timepoints 5 years apart in the period 2005-19 where possible. Life expectancy from a given age was computed as the area under the survival curves and lifetime lost was calculated as the difference between the expected lifetime of people with versus without type 2 diabetes at a given age. Lifetime risk was calculated as the proportion of each cohort who developed type 2 diabetes between the ages of 20 years and 100 years. We estimated 95% CIs using parametric bootstrapping. FINDINGS: Across all study cohorts from the 23 jurisdictions (total person-years 1 577 234 194), there were 5 119 585 incident cases of type 2 diabetes, 4 007 064 deaths in those with type 2 diabetes, and 11 854 043 deaths in those without type 2 diabetes. The lifetime risk of type 2 diabetes ranged from 16·3% (95% CI 15·6-17·0) for Scottish women to 59·6% (58·5-60·8) for Singaporean men. Lifetime risk declined with time in 11 of the 15 jurisdictions for which two timepoints were studied. Among people with type 2 diabetes, the highest life expectancies were found for both sexes in Japan in 2017-18, where life expectancy at age 20 years was 59·2 years (95% CI 59·2-59·3) for men and 64·1 years (64·0-64·2) for women. The lowest life expectancy at age 20 years with type 2 diabetes was observed in 2013-14 in Lithuania (43·7 years [42·7-44·6]) for men and in 2010-11 in Latvia (54·2 years [53·4-54·9]) for women. Life expectancy in people with type 2 diabetes increased with time for both sexes in all jurisdictions, except for Spain and Scotland. The life expectancy gap between those with and without type 2 diabetes declined substantially in Latvia from 2010-11 to 2015-16 and in the USA from 2009-10 to 2014-15. Years of life lost to type 2 diabetes ranged from 2·5 years (Latvia; 2015-16) to 12·9 years (Israel Clalit Health Services; 2015-16) for 20-year-old men and from 3·1 years (Finland; 2011-12) to 11·2 years (Israel Clalit Health Services; 2010-11 and 2015-16) for 20-year-old women. With time, the expected number of years of life lost to type 2 diabetes decreased in some jurisdictions and increased in others. The greatest decrease in years of life lost to type 2 diabetes occurred in the USA between 2009-10 and 2014-15 for 20-year-old men (a decrease of 2·7 years). INTERPRETATION: Despite declining lifetime risk and improvements in life expectancy for those with type 2 diabetes in many high-income jurisdictions, the burden of type 2 diabetes remains substantial. Public health strategies might benefit from tailored approaches to continue to improve health outcomes for people with diabetes. FUNDING: US Centers for Disease Control and Prevention and Diabetes Australia.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Tomic D, Morton JI, Chen L, et al. Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study. Lancet Diabetes Endocrinol. 2022. PMID: 36183736. doi:10.1016/S2213-8587(22)00252-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。